| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 06/03/2004 | US20040105840 Protein conjugates with a water-soluble biocompatible, biodegradable polymer |
| 06/03/2004 | US20040105839 Biologically active non-antigenic copolymer and conjugates thereof and methods for producing the same |
| 06/03/2004 | US20040104501 Method for injection moulding moulded bodies consisting of (meth) acrylate copolymers |
| 06/03/2004 | US20040103902 Condom with an erectogenic composition |
| 06/03/2004 | DE10255285A1 Selbst formende Phospholipid-Gele Self-forming phospholipid gels |
| 06/03/2004 | DE10254745A1 New aldonic acid imidazolides of starch compounds selectively oxidized at the reducing terminal, useful for coupling with amino functions of pharmaceutically active agents, e.g. proteins |
| 06/03/2004 | DE10253623A1 Bioabbaubare kolloidale Partikel, insbesondere für pulmonale Applikationen Biodegradable colloidal particles, in particular for pulmonary applications |
| 06/03/2004 | DE10253042A1 Kosmetische Zubereitung enthaltend einen Komplex aus Cyclodextrin und Vitamin F A cosmetic preparation containing a complex of cyclodextrin and vitamin F |
| 06/03/2004 | DE10133305B4 Ubichinon Konzentrat Ubiquinone concentrate |
| 06/03/2004 | CA2545877A1 Biodegradable colloidal particles for pulmonary applications in particular |
| 06/03/2004 | CA2514089A1 Activation of peptide prodrugs by hk2 |
| 06/03/2004 | CA2506842A1 Amplification of biotin-mediated targeting |
| 06/03/2004 | CA2506317A1 Method for continuous, automated blending of solutions from acids and bases |
| 06/03/2004 | CA2506241A1 Bioerodible poly(ortho esters) from dioxane-based di(ketene acetals), and block copolymers containing them |
| 06/03/2004 | CA2505833A1 Edible film for relief of cough or symptoms associated with pharyngitis |
| 06/03/2004 | CA2505717A1 Use of multi-specific, non-covalent complexes for targeted delivery of therapeutics |
| 06/03/2004 | CA2504267A1 Interferon-alpha polypeptides and conjugates |
| 06/03/2004 | CA2503316A1 Method and compositions for temporarily incapacitating subjects |
| 06/03/2004 | CA2503312A1 Method and compositions for treating persistent pulmonary hypertension using aralkyl ester soft drugs |
| 06/03/2004 | CA2502025A1 Pharmaceutical compositions having a modified vehicle |
| 06/03/2004 | CA2501978A1 Pharmaceutical composition comprising octreotide microparticles |
| 06/02/2004 | EP1424343A1 Peptide Conjugate useful for cell nucleus molecular imaging and tumor therapy |
| 06/02/2004 | EP1424342A1 Nucleic acid comprising a sequence encoding a modified glutenin polypeptide |
| 06/02/2004 | EP1424081A1 Polysaccharide-containing compositions and use thereof |
| 06/02/2004 | EP1424076A1 Use of green coffee extract as mineral absorption enhancer |
| 06/02/2004 | EP1424069A2 Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
| 06/02/2004 | EP1424066A1 Dry compositions comprising hydrophobic stabilisers |
| 06/02/2004 | EP1423412A2 Homing peptides |
| 06/02/2004 | EP1423406A2 Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
| 06/02/2004 | EP1423404A2 RNA INTERFERENCE MEDIATED TREATMENT OF ALZHEIMER'S DISEASE USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 06/02/2004 | EP1423154A2 Hydrogenated castor oil dispersed in a lipid for pharmaceutically elegant topical ointments |
| 06/02/2004 | EP1423151A1 Light-stabilized $i(in vivo) stain composition and method of manufacture |
| 06/02/2004 | EP1423150A2 Sustained release of microcrystalline peptide suspensions |
| 06/02/2004 | EP1423147A1 Prostaglandin compositions and methods of treatment for male erectile dysfunction |
| 06/02/2004 | EP1423142A1 Helicobacter pylori vaccination with a combination of caga, vaca and nap proteins |
| 06/02/2004 | EP1423138A2 Use of il-18 inhibitors in hypersensitivity disorders |
| 06/02/2004 | EP1423136A1 Polypeptide conjugates with extended circulating half-lives |
| 06/02/2004 | EP1423126A2 Treatment of hyperproliferative conditions of body surfaces |
| 06/02/2004 | EP1423124A2 Lyophilized formulation comprising olanzapine |
| 06/02/2004 | EP1423118A1 Method and composition for treatment of cancer |
| 06/02/2004 | EP1423109A2 Compositions comprising pectin and ascorbic acid |
| 06/02/2004 | EP1423102A1 Plaster for the treatment of dysfunctions and disorders of nail growth |
| 06/02/2004 | EP1423100A1 Plaster for the treatment of dysfunctions and disorders of nails, comprising sertaconazole |
| 06/02/2004 | EP1423099A1 A new extended release oral dosage form |
| 06/02/2004 | EP1423098A1 A new extended release oral dosage form |
| 06/02/2004 | EP1423095A1 Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy |
| 06/02/2004 | EP1423094A2 A new method |
| 06/02/2004 | EP1423092A2 Functional powders for oral delivery |
| 06/02/2004 | EP1423088A2 Stabilisation of oxidation-sensitive and uv-sensitive active ingredients |
| 06/02/2004 | EP1423081A2 Composition comprising glycosaminogycans and hyaluronidase inhibitors for the treatment of arthritic joints |
| 06/02/2004 | EP1423019A1 Process for preparing concentrate thickener compositions |
| 06/02/2004 | EP1380639A8 Method for producing a water-alcohol solution and products based thereon |
| 06/02/2004 | EP1274405B1 Transdermal or transmucosal dosage forms with a nicotine-containing active substance combination for smoker disintoxication |
| 06/02/2004 | EP1267832B1 SELF EMULSIFYING DRUG DELIVERY SYSTEM, wherein the fatty agent is optional |
| 06/02/2004 | EP1227824B1 Transplant/implant device and method for its production |
| 06/02/2004 | EP1169378A4 Preparing porous hydrogel products |
| 06/02/2004 | EP1100344B1 Chitosan-containing liquid compositions and methods for their preparation and use |
| 06/02/2004 | EP1098635B1 Enteric coated pharmaceutical tablet containing didanosine |
| 06/02/2004 | EP1063978B1 Method of treating neuroma pain |
| 06/02/2004 | EP1056445B1 Orally administrable immediate-release and prolonged-release galenic form comprising an absorption-promoting agent and use of this absorption-promoting agent |
| 06/02/2004 | EP1016409B1 Freeze dried composition comprising glycosphingolipids |
| 06/02/2004 | EP0948965B1 Stable medicinal compositions containing 4,5-epoxymorphinane derivatives |
| 06/02/2004 | EP0941334B1 Protease-activatable pseudomonas exotoxin a-like proproteins |
| 06/02/2004 | EP0828500B1 Use of flavanolignanes for the preparation of medicaments with antiproliferative activity in uterus, ovary and breast |
| 06/02/2004 | EP0769966B1 Biotin compounds for targetting tumors and sites of infection |
| 06/02/2004 | CN1501909A Novel succinate salt of o-desmethyl-venlafaxine |
| 06/02/2004 | CN1501903A Stable solution of reduced coenzyme q |
| 06/02/2004 | CN1501814A Pharmaceutical compositions |
| 06/02/2004 | CN1501811A Compositions for stimulating cytokine secretion and inducing an immune response |
| 06/02/2004 | CN1501804A Acrochordon alleviation |
| 06/02/2004 | CN1501799A Composition for the prevention of osteoporosis comprising a combination of isoflavones and polyunsaturated fatty acids |
| 06/02/2004 | CN1501776A Microcapsules |
| 06/02/2004 | CN1501773A Liquid formulations for dernal application in treatment of parasitic insects in animals |
| 06/02/2004 | CN1500820A Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
| 06/02/2004 | CN1500524A Vehicle for topical delivery of anti-inflammatory compounds |
| 06/02/2004 | CN1500475A Diffusional implantable delivery system |
| 06/02/2004 | CN1152067C Aqueous high molecular film material for medicine coating |
| 06/02/2004 | CN1151845C Crystallographically stable amorphous sephalosporin compositions and process for producing the same |
| 06/02/2004 | CN1151844C Preparation of pharmaceutical active granules |
| 06/02/2004 | CN1151836C Compounds and compositions for delivering active agents |
| 06/02/2004 | CN1151799C Bacterial membrane fractions with adjuvant effect |
| 06/02/2004 | CN1151791C Sustained-release composition containing cefaclor |
| 06/02/2004 | CN1151783C Delayed-release dosage forms of sertraline |
| 06/02/2004 | CN1151782C Medicinal injection liquid of anaesthesia induction and keeping and sedation of mammalian |
| 06/02/2004 | CN1151780C Solubility paramete based drug delivery system and method for altering drug saturation concentration |
| 06/02/2004 | CN1151779C Two-piece capsule for receiving pharmaceutical preparations for powder inhalers |
| 06/02/2004 | CN1151778C Pharmaceutical composition comprising entacapone or nitecapone as well as cross-linked cellulose derivative |
| 06/02/2004 | CN1151775C Method of treating dry eye disease with purinergic receptor agonists |
| 06/01/2004 | US6743930 Kernel oil from plant kernel, process for extracting same, pharmaceutical composition and thereof |
| 06/01/2004 | US6743908 For use in cancer diagnosis and therapy |
| 06/01/2004 | US6743896 Protien for use in the treatment of infection and tumors |
| 06/01/2004 | US6743893 Receptor-mediated uptake of peptides that bind the human transferrin receptor |
| 06/01/2004 | US6743892 Molecules that home to a selected organ in vivo |
| 06/01/2004 | US6743880 Introducing monomeric 2- hydroxyethyl methacrylate containing ethylene glycol, dimethacrylate impurities, and atleast one acrylic or methacrylic acid into a solution of water and alcohol, and copolymerizing the monomers |
| 06/01/2004 | US6743826 Delivery of compounds having poor water solubility; binding affinity to plasma proteins by way of non-covalent bonds; serum albumin and gamma globulin; paclitaxel, amphotericin b, camptothecin, carbamazepine, cyclosporin a; propofol |
| 06/01/2004 | US6743783 Pharmaceutical compositions comprising poly-β-1→4-N-acetylglucosamine |
| 06/01/2004 | US6743781 Glycerolipid compounds useful for the transfer of an active substance into a target cell |
| 06/01/2004 | US6743775 Slow release formulations comprising anionic polysaccharide |
| 06/01/2004 | US6743585 Complexing in solvent |
| 06/01/2004 | US6743577 Methods of using cyanovirins to inhibit viral infection |